CD274 and neoplasm: The expression of PD-L1 on at least 50% of tumour cells in immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded (FFPE) tissue sections is a mandatory test used in some medical centres for prescribing Pembrolizumab as first-line monotherapy in NSCLC [16].